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Lack of nephritogenicity of systemic activation
of the alternate complement pathway
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Lack of nephritogenicity of systemic activation of the alternate
complement pathway. To assess the nephritogenicity of non-
immune systemic complement activation as a possible model of
human chronic hypocomplementemic glomerulonephritis, rab-
bits were given a regimen of inulin or zymosan, known activators
of the alternate complement (C) pathway. Acute infusions of
these particulate activators produced glomerular deposits of C3,
C6 and fibrin, in addition to glomerular accumulation of
polymorphonuclear leukocytes. The fibrin deposits suggest that
complement activation by inulin or zymosan particles trapped in
the glomerular capillaries may have triggered the coagulation
system. In chronic C activation (produced by daily administra-
tions of inulin or zymosan), giant cells formed in the kidney and
other organs secondary to phagocytosis of the particulate
activators. Although both agents produced marked hypo-
complementemia, only 12 of 68 rabbits became proteinuric after
as many as 39 weeks of injection (compared with three of 25
age-matched control rabbits). Ten of these rabbits had granular
glomerular deposits of C3 accompanied by IgG. The immuno-
histochemical characterization of the glomerulonephritis in these
rabbits, as well as its low frequency of occurrence, and the ab-
sence of correlation with the amount of inulin or zymosan ad-
ministered suggest that it was the emergence of a presumed
immune complex glomerulonephritis which occurs sponta-
neously in our colony. Systemic nonimmune C activation then
appears insufficient to induce glomerulonephritis in rabbits.
Absence de néphritogénicité chez le lapin de l'activation
systémique non immune de Ia voie alterne du complement (C).
Divers groupes de lapins ont été injectés avec des activateurs con-
nus de la voie alterne d'activation du C tels que l'inuline et le
zymosan, afin d'étudier la nephritogenicite de l'activation non
immune du complement comme modèle possible de glomérulo-
pathie hypocomplementémique. L'administration aiguë de ces
activateurs particulaires produit des dépôts glomérulaires de C3,
C6 et de fibrine ainsi que I'infiltration des glomerules par des
polynucléaires. Les dépôts de fibrine suggérent que les particules
d'inuline ou de zymosan bloquées dans les capillaires gloméru-
laires ont active le système de coagulation. Lors de l'activation
chronique du C (produite par l'administration quotidienne
d'inuline ou de zymosan) l'on constate la formation de cellules
geantes dans les glomérules et dans les autres organes, probable-
ment secondaire a Ia phagocytose de ces activateurs particu-
laires. Bien que ces deux agents aient induit une hypocomple-
mentemie intense, 12 sur 68 lapins seulement ont développe une
protéinurie après un maximum de 39 semaines d'injection. alors
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que 3 sur 25 lapins contrôles d'âge semblable ont également
développé une protèinurie. Dix de ces lapins avaient des dépôts
de C3 et d'IgG. Les caractères immunohistochimiques de cette
néphropathie, sa faible fréquence, l'absence de correlation avec
la quantité d'inuline ou de zymosan administrée, suggèrent qu'il
s'agit en fait d'une glomérulonéphrite qui survient spécifique-
ment dans notre colonie, probablement secondaire au depot
d'immuns complexes. L'activation systémique non immune de
C ne semble donc pas a elle seule susceptible d'induire une
glomérulonéphrite chez ce lapin.
Observations in animals and man have defined two
different mechanisms that lead to glomerulonephritis.
These mechanisms are easily distinguished by the
immunofluorescent pattern of immunoglobulins (Ig)
bound in the glomeruli: granular deposits are typical of
nonglomerular antigen-antibody complexes, while
smooth linear deposits characterize antiglomerular
basement antibody [1]. It is believed that both anti-
body-induced mechanisms may cause injury via the
complement (C) system [1]. Measurements of serum
C concentrations [2] and immunofluorescence studies
showing both early (CIq and C4) and late (C5, C6,
C8) C component deposition in glomeruli [3] indicate
that in most instances the entire C sequence is utilized,
which in turn suggests classical C activation, perhaps
with additional C activation by C3b feedback activa-
tion of the alternate C pathway [4]. In a number of
patients, usually those with advanced stages of
glomerulonephritis, only deposits of C3 and later
components (C5, C6, C8) can be detected in the
absence of Ig and early C components (CIq, C4) [3].
Furthermore, in chronic hypocomplementemic gb-
merulonephritis (CHGN), C deposition, sometimes in
the absence of detectable immunogbobulin [5, 6], is
accompanied by a decrease in late but not in early
serum C components [7]. Since the C sequence can be
activated by an alternate, nonimmunologic pathway
[8] (starting at C3 and bypassing Cl, C4 and C2), one
can hypothesize that nonimmune C activation by the
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alternate pathway might lead to glomerular injury.
Sera of patients with CHGN have been found to
contain a factor capable of activating C3 and the later
components of the C system [9], probably via the
alternate C pathway [10]. Recent studies have sug-
gested that the factor may be an early component of the
alternate C pathway, acting before properdin [11, 12].
As yet, however, no evidence demonstrates the role
nonimmune C activation might play in the patho-
genesis of glomerular lesions.
This study was designed to determine any possible
nephritogenic effects of systemic nonimmune activation
of the alternate complement pathway in rabbits. Inulin
and zymosan, known activators of the alternate C
pathway [8], were administered i.v. either acutely or
daily for up to 39 weeks and the effects on systemic
complement levels and glomerular immunopathologic
changes observed.
Methods
Laboratory animals. New Zealand white rabbits
weighing 2 to 2.5 kg and having no proteinuria for two
consecutive baseline 24-hr urine collections were used
for this study.
Inulin and zymosan preparations. Particulate inulin
was purchased from Pfanstiehl Laboratory (Waukegan,
IL) and used in three different preparations. The first
(Inulin A) was a suspension of particulate inulin in
nonpyrogenic saline at a concentration of 75 mg/ml.
A more finely dispersed preparation (Inulin B) was
obtained by heating Inulin A for four minutes at 56°C.
The third preparation (Inulin C) was the supernate
remaining after Inulin B was centrifuged at 300 x g for
30 mm in order to remove any coarse particles (centri-
fugation resulted in a loss of 10% of the total material).
Zymosan was purchased from Nutritional Bio-
chemical Company (Cleveland, Ohio) and suspended
in nonpyrogenic saline solution at a concentration of
10 mg/mi. Prior to use, this suspension was "activated"
by incubation at 100°C for 30 mm and cooled to room
temperature.
Acute administration. Over periods of one to ten
hours, Inuiin A was continuously infused at 1125 mg/
hr into the ear veins of five rabbits and Inulin B and C
at 1500 and 1350 mg/hr into three and four rabbits,
respectively. In two of the latter rabbits, infusions of
Inulin C were repeated on four consecutive days for
seven hours each day. Three rabbits were infused with
zymosan at a rate of 40 mg/hr for ten hours. Blood
was obtained for C determinations before and
immediately after each infusion. The concentration of
protein in bladder urine was monitored at the comple-
tion of all infusions.
Chronic administration. For periods up to 39 weeks,
38 rabbits were given one to six 150-mg i.v. injections
of Inulin A daily, as follows: one dose, 6 rabbits; two
doses, 16 rabbits; three doses, 11 rabbits; and six doses,
5 rabbits. Three rabbits received 2250 mg of Inulin B,
daily, in three divided doses. Five rabbits were given
2430 mg of Inulin C, daily, in three divided doses.
Using six dosages, 40 rabbits were given daily in-
jections of zymosan for up to 30 weeks, as follows:
25 mg, ten rabbits; 50 mg, eight rabbits; 75 mg, four
rabbits; 100 mg, four rabbits; 150 mg, ten rabbits; and
200 mg, four rabbits.
During the period of injection, 24-hr protein
excretion was monitored weekly. Whole hemolytic C
and C3 measurements were performed weekly before
and after injection in all the rabbits receiving zymosan
and in two rabbits of each inulin regimen. Surgical
renal biopsies were performed when proteinuria was
detected, and systematically every two months in
rabbits receiving zymosan.
Control observations. A group of 25 control rabbits
of comparable mean and median age to the rabbits
used in the chronic administration experiments (14 to
52 weeks) were housed in metabolic cages for 14 days
for proteinuria detection. The rabbits were then killed
for histologic, immunofluorescence and electron micro-
scopic studies to determine the appearance and inci-
dence of spontaneous renal alterations in our colony.
Proteinuria and inulin excretion. Twenty-four-hour
protein excretion was measured weekly in the chronic
administration rabbits by the sulfosalicylic acid
method [13]. Abnormal proteinuria was defined by two
consecutive measurements above 20 mg/24 hr. Urinary
excretion of inulin was measured by a modification
of the method of Schreiner [14].
Complement determinations. Blood for C measure-
ments was obtained from the ear artery and allowed to
stand at room temperature for 30 mm and on ice for
one hour. The serum was then separated by centri-
fugation and stored at —70°C. For hemolytic C
titrations all dilutions were made in veronal-buffered
saline containing Ca , Mg and 0.1% (wt/vol)
gelatin (GYB).
CH5O determinations of whole C hemolytic activity
were performed by a slight modification of the macro-
method [15] using 0.8 to 2.4 ml of appropriately
diluted serum and 0.4 ml of 5 x 108 sensitized erythro-
cytes (EA), for a total volume of 3 ml. The mean value
of 20 normal rabbits was 27.0± 7.1 U.
C3 determinations were made by radial immuno-
diffusion [16]. Results were expressed as the percent
of the C3 present in a pool of normal rabbit serum
which was used throughout the study. The mean value
for 20 normal rabbits was 108 18.7%.
S 
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C6 determinations were made using C6-deficient
rabbit serum as a source of C [17]. Appropriately
diluted test serum, 10 to 100 1; 100 il of C6-deficient
serum diluted 1:4; 200 tl of 5 x 108 EA; and a suffi-
cient amount of GYB to obtain a final volume of 0.4
ml were mixed and incubated at 37°C for 60 mm. The
reaction was stopped by addition of 2 ml of cold saline
and immediate centrifugation at 4°C. Free hemo-
globin was quantitated spectrophotometrically and C6
determined hemolytically.
Antiinulin and antizymosan antibodies. Antiinulin
antibodies were sought in serum diluted 1: 10 by a
modified Farr technique [18], utilizing 3H-inulin (New
England Nuclear, Boston, MA) at concentrations of
1, 10 and 100 ig/ml.
Antizymosan antibodies were detected by indirect
immunofluorescence. Heat-activated zymosan, 0.3
mg, was incubated for 30 mm at 37°C with 50 1 of
the appropriate dilution of serum to be tested. This
suspension was then centrifuged, washed twice with
phosphate-buffered saline (PBS) and the sediment
further incubated for 30 mm at room temperature
with 50 l of fluorescein isothiocyanate (FITC)-
labeled goat antirabbit IgG. The zymosan particles
were then centrifuged, washed in PBS, resuspended in
100 il of PBS, mounted on slides and examined under
the fluorescence microscope.
Radiolabeling procedure, clearance and organ locali-
zation of zymosan. Zymosan particles were labeled
with 125J as by the method of McConahey and Dixon
[19]. Two rabbits were given 2 mg of 1251-labeled
zymosan and the trichloroacetic acid precipitable
counts in their blood were determined at 30-sec
intervals to ascertain zymosan's rate of disappearance
from the circulation. The rabbits were killed one hour
after zymosan administration and the organ localiza-
tion was determined.
Pathological studies. For routine histologic observa-
Fig. 1. Comparison of the size (A) of Jim/in A crystals
(_*) and (B) zymosan particles (—*) with the size
of rabbit red blood cells (H->) (phase microscopy,
original magnification, x 500).
tions, tissue samples obtained at biopsy or autopsy
were fixed in Bouin's solution, postfixed in 50% ethyl
alcohol and stained with hematoxylin-eosin and
periodic acid Schiff (PAS). For electron microscopy
small fragments of kidney tissue were diced in 2%
glutaraldehyde, postfixed in 1% osmic acid, dehydra-
ted, and embedded in Vestopal W (Henley and Co.,
Inc. New York, NY). Sections obtained on an auto-
matic microtome (LKB) were stained with 2% uranyl
acetate and 0.5% lead citrate and examined with an
electron microscope (Hitachi 11A).
Direct immunofluorescence studies [20] were per-
formed with the following fluorescein isothiocyanate
(FITC)-conjugated antisera: goat antirabbit IgG,
sheep antirabbit C3, guinea pig antirabbit fibrin and
goat antirabbit albumin. The goat antirabbit C6 was
used in an indirect immunofluorescence system with an
FITC-labeled rabbit antigoat IgG as a second layer.
Results
Inulin and zymosan preparations. In Fig. 1, one can
see that the particles of Inulin A had a crystalline
appearance and varied in size; some were as large as a
rabbit red blood cell, but the majority were con-
siderably smaller. Initial studies indicated that the
maximum dose of this preparation that could be
administered safely in a single injection was 100 to
150 mg. In contrast, the Inulin C preparation con-
tained only very fine particles and could be given in
considerably larger amounts of between 650 and 800
mg. The composition of Inulin B was very similar to
that of Inulin C but contained a few larger particles.
Insufficient quantities of radiolabeled inulin were
available for determining the initial localization of the
particles. Measurements of urine excretion indicated
that 60 to 80% of the inulin given daily was excreted
within 24 hr.
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Table 1. Effect of acute infusions of inulin or zymosan on glomerular pathology and serum C concentrations
C activator
infused
Animals
N
Amount of
C activator
infused
°/ decreasea of PMN
in glomeruli
Immunofluorescence
CH5O C3 C6 IgG C3 C6 Fibrin
mga PMNb Rabbits O—tr 1—3+ 1—3+ 1—3+
N N
Inulin A 5 4,350 50 32 58 2—10 1
5—20
1/5 1/5 1/5 1/5
Inulin B 3 4,275 59 28 75 2—10 3 3/3 3/3 3/3 3/3
Inulin C 4 7,425 51 52 66 2—10 3 3/4 3/4 3/4 3/4
Zymosan 3 400 60 — 73 2—10 2
5—20 1
0/3 3/3° 3/3° 2/2
.
a Mean of all animals studied.
b Normally, 0 to 2 polymorphonuclear leukocytes (PMN's) are present per glomerulus.
Detected on zymosan particles and on segments of adjacent capillary wails.
A preparation of zymosan is also shown in Fig. 1,
where the sizes of the ovoid particles can be compared
to those of rabbit red blood cells. By using '251-labeled
zymosan, it was possible to demonstrate that almost
all the injected zymosan was cleared from the circu-
lation within two minutes. After 60 mm 35% of the
injected dose was located in the lungs, 21% in the
liver, 1% in the spleen, and 1.7% in the two kidneys.
Acute administration (Table 1). Nine of the 15
rabbits infused with large amounts of inulin or
zymosan suspensions died during the process. Of the
remaining rabbits, four were killed after the first
infusion and the other two after four consecutive
infusions. The amounts of inulin or zymosan infused
are given in Table 1. Bladder urine obtained after the
infusion was found to be free of protein in all cases.
1) Complement determination. CH5O, C3 and C6
measurements were obtained in 11 rabbits before
infusions were started and after they were finished. In
all cases there were 28 to 75% decreases in CH5O, C3
and C6. In the two rabbits that were infused on four
consecutive days, serum C remained depressed after
the initial infusion, and subsequent infusions did not
cause it to become appreciably more depressed.
2) Immunopathology. Light microscopy showed that
in eight rabbits given inulin and in three rabbits given
zymosan, most glomeruli contained polymorpho-
nuclear leukocytes (PMN). In the three rabbits in-
fused with zymosan, zymosan particles were found in
the glomerular and peritubular capillary lumens.
Glomerular capillary walls were of normal thickness;
there was no increase in the number of endocapillary
cells, and no abnormal deposits could be detected in
the mesangium. Zymosan particles were also present in
Fig. 2. C3 deposits (accompanied by C6 and
fibrin in the virtual absence of IgG) in the
glomerulus of a rabbit that had received 1125mg
of maim A/hr Lv. for eight hours (fluorescein
isothiocyanate conjugated sheep ant irabbit C3;
original magnification, x 250).
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the lungs, spleen and liver where they were accom-
panied by varying degrees of polymorphonuclear
infiltration. In seven rabbits infused with inulin,
immunofluorescence demonstrated the presence of
focal deposits (Fig. 2) containing large amounts of C3,
C6 and fibrin, along with trace amounts of 1g. In the
three rabbits injected with zymosan, C3 and C6 could
be found on the zymosan particles as well as focally
along segments of the adjacent glomerular capillary
walls. Fibrin was deposited along the glomerular
capillary walls and in the capillary lumens in the
zymosan rabbits studied.
Chronic administration. Two groups of rabbits (one
group of 40 and one of 46) were subjected to pro-
Table 2. Proteinuria in 12 rabbits given inulin or zymosan over prolonged periods
Daily dose of C
activatora
Proteinuric
animals
N
First positive
proteinuriab
Mean 24-hr
protein excretion
mg±SD
Duration of
proteinuriac
weeks
Inulin A
150mg 1/6d 6 73±4 33
InulinA
300mg 3/16
2
2
14
325±217
251±171
103±65
34
10
9
Inulin C
2430mg 1/3 13 70±46 7
Zymosan
25mg 2/10
6
6
83±68
100±47
18
8
Zymosan
50mg 3/8
4
10
11
395±223
64±42
68±27
21
19
18
Zymosan
75mg 1/4 22 47±31 8
Zymosan
100mg 1/10 1 587±278 1
None of the animals receiving Inulin B or higher doses of Inulin A or zymosan developed proteinuria.
' Weeks after first injection.
o Duration from onset till death or sacrifice.
d Total number of animals receiving the same dose of C activator.
Zymosan
200mg
150mg
100mg
75mg
50mg
25mg
I I I I I I II
.j,
I I I
"1"i'"l""i 2430 mgi I I
2250mg
I I I I
900mg
450mg
Inulin C ___________________
Inulin B
_________
Inulin A _______________
Inulin A _____________
Inulin A
Inulin A
I I I
Fig. 3 Daily dosages of zymosan or maim
administered i.v. to the rabbits, along with
their survival times.
•
16 24
Weeks
150mg
8 16243240
D Spontaneous death Weeks
Sacrificed
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longed administration of zymosan, and the various
inulin suspensions. As indicated in Fig. 3, none of the
rabbits receiving more than 75 mg of zymosan or 450
mg of Inulin A or Inulin B survived more than 10 to
22 weeks. In most cases, death occurred in the minutes
immediately after the injections, suggesting a mech-
anical, perhaps embolic, role of the particles injected.
Abnormal protein excretion was detected between 1
and 22 weeks after the first injection in five rabbits
receiving inulin and seven rabbits receiving zymosan
suspensions (Table 2). The magnitude of proteinuria
was variable but, once established, persisted until the
rabbit died or was killed. Three of 25 control rabbits
had proteinuria.
1) Complement determinations. The depressant effect
of the various inulin and zymosan preparations on
CH5O concentration over a period of 24 hr is de-
picted in Fig. 4, A and B. The three inulin prepara-
tions had similar effects, producing a 45 to 60%
decrease within 1 to 4 hr, with a return to normal
values at 24 hr in the case of Inulin A, and persistent
20% decreases after the larger doses of Inulin B and
Inulin C. Administration of zymosan in doses of 25
and 50 mg effected a prompt 25 to 30% decrease with
a return to normal values within 24 hr. Doses of
zymosan above 75 mg effected a prompt decrease of
40 to 50% that lasted 24 hr. The effects of administra-
tion of 100 mg of zymosan or repeated injections of
150 mg of Inulin A on C3, C6 and CH5O concentra-
tions depicted in Fig. 5,A and B. In both instances
there was a simultaneous decrease in these three
measurements. Fig. SB further demonstrates that a
C-)
C)0,ct
C)
Ct
C)C-
C)
C)
Time, hr Time, hr
Fig. 4. The mean (two rabbits)
percent decrease in total hemo-
lytic complement (CH50) over
a 24-hr period for various,
single i.v. doses of zymosan(A) and the percent decrease
after i.v. administration of
150mg of Inulin A, 750mg of
maIm B and 810 mg of Inidin
C(B).
Fig. 5. Mean (two rabbits)
percent decrease in C3, C6 and
CHSO after i.v. administration
of zymosan (100 mg) (A) or
three successive doses (150 mg
each) of maIm A (B).
8 12 16 20
Time, hr Time, hr
Zymosan Inulin A
150mg
Renal effects of systemic alternate C activation 163
Table 3. Effect of chronic i.v. injections of inulin or zymosan on serum CH5O and C3 concentrations0
Dose of C
activator
given/24 hr
CH5O C3
U/mi before % decrease 3 hr % of normal decrease 3 hr
injection of after injection pool before after injection
activatorb of activator0 injection of of activator0
activator0
Inulin A
150mg 16±3 21±11 84±20 31±12
Inulin A
300mg 19±9 22±14 88±23 24±14
Inulin A
450mg 25± 13 21± 12 92±24 24± 14
Inulin A
900mg 23±9 23±15 72±7 22±8
Inulin B
2250mg 20±7 21±12 102±17 16±11
Inulin C
2430mg 23±5 17±8 102±25 18±15
Zymosan
25mg 26±12 28±14 88±33 27±12
Zymosan
50mg 29±12 32±16 76±24 31±13
Zymosan
75mg 25±11 61±23 71±26 41±16
Zymosan
100mg 26±8 60±28 96±17 23±9
o Weekly measurements of CH5O and C3 were obtained on serum samples drawn before and three hours after
the first (or only) injection of the day, and the percent decrease calculated.
Mean values for each experimental group.
second injection of 150 mg of inulin induced a further
decrease in C3, C6 and CH5O concentrations.
The mean results of the weekly C measurements
obtained over the entire experimental period are
summarized in Table 3. There was a considerable
weekly variation in both C3 and CH5O concentration
as measured before injection of inulin or zymosan. No
consistent trend in preinjection C concentrations was
found in the rabbits receiving inulin. However, in nine
of the 14 rabbits that received zymosan and survived
more than four weeks, there was a transient rise in the
C concentration sometime between the second and
fifth week. Administration of the C activator with rare
exceptions resulted in a decrease in C concentration.
The percentage decrease in C was consistently greater
in some rabbits than others on the same dosage. The
mean percent change in C concentration after injec-
tions of zymosan or inulin was the same throughout
the experiment in all animals receiving inulin or small
doses of zymosan. In the three rabbits receiving 75 or
100 mg of zymosan, the percentage change in CH5O
increased slightly, from 50 to 70%. Rabbits receiving
larger doses did not survive long enough for meaning-
ful data to be gathered.
2) Antiinulin and antizymosan antibodies. Antiinulin
and antizymosan antibodies were sought in serum
samples collected prior to one of the last zymosan or
inulin injections. Antiinulin antibodies could not be
detected in any of the serum specimens studied, not
even after dialysis of the samples against large vol-
umes of 3.5 M sodium thiocyanate to dissociate and
remove any possible immune-complexed inulin. Anti-
zymosan antibodies were detected in 1 :40 serum from
ten of 24 rabbits that had received zymosan for periods
varying from 8 to 30 weeks. Five of 14 rabbits given a
regimen of zymosan for less than eight weeks had
antizymosan antibodies at titers of 1:5 or 1: 10.
3) Immunopathology. Interpretation of the renal his-
tologic alterations in both the nonproteinuric (Table 4)
and proteinuric (Table 5) rabbits was complicated by
glomerular giant cells presumably resulting from
ingestion of particulate inulin or zymosan particles by
fixed or circulating phagocytic cells (Fig. 6). Similar
observations have been made after administration of
other particulate materials such as polyvinyl pyroli-
dome [21]. The frequency and size of the multi-
nucleated giant cells appeared related to the amounts
of either inulin or zymosan administered, and in some
instances they virtually replaced the normal glomerular
architecture without apparent functional alteration.
Electron microscopy revealed that the giant cells
contained either striated crystalloid material (in the
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Table 4. Immunopathologic findings in 76 renal specimens from 74 rabbits that did not develop proteinuria during chronic i.v.administration
of inulin and zymosan compared with 22 age-matched nonproteinuric control rabbits
Inulin preparations Zymosan Control
0—8 weeks 8—16 weeks >16 weeks 0—8 weeks 8—16 weeks >16 weeks
A B&C A B&C A B&C 25-75 100-200 25-75 100-200 25-75
mg mg mg mg mg
Renal specimens studied, N 13 3 2 3 17 2 14k' 15 3b 1 3 22
Endothelial proliferation
Mild and/or focal 4 1 3 4 6 4 1 1 2 8
PMN in glomeruli
2—lO/glomerulus 3 1 1 2
PAS-positive mesangial
deposits
Moderate to marked 2 2 1 3 5 2 8 2 1 1 3 7
Giant cellsc
0—2/glomerulus 4 1 1 9 1 1
1—3> /glomerulus 2 3 1 2 1 6 1
Tubulointerstitial damage
Moderate to severe 3 2 1 1 1 3
Immunofluorescence
IgG, C3, C6
tr-l + focal granular 7 1 11 8 7d 2 2 9d
PMN, polymorphonuclear leukocytes; PAS, periodic acid Schiff.
One specimen not studied by immunofluorescence.
Very large multinucleated cells in glomeruli.
1 One specimen had C3 and C6 deposits without lgG.
Table 5. Immunopathologic findings in 28 renal specimens from 12 rabbits that developed proteinuria during chronic i.v. administration of
inulin and zymosan compared with three age-matched proteinuric control rabbits
Inulin preparations Zymosan Control
0—8 weeks 8—16 weeks > 16 weeks 0—8 weeks 8—16 weeks > 16 weeks
A A C A C 25—75 100—200 25—75 25—75
mg mg mg mg
Renal specimens studied, N 4 2 1 4 1 6 1 4 5 3
Endothelial proliferation
Mild and/or focal 2 1 1 2 1 3 2
Severe 1 2 D 1 2 1
PMN in glomeruli
2—lO/glomerulus 1 1 1 2 2 3
5> 20/glomerulus 1 2 1 1 2
PAS-positive mesangial
deposits
Moderate to marked 2 2 4 1 4 1 3 5 3
Giant cellsb
0—2/glomerulus 2 1 3 1
1—3> /glomerulus 1 1
Tubulointerstitial damage
moderate to severe 2 1 2 1 3 5 2
Immunofluorescence
tr- 1 + focal granular 0 2 1 2
1- 3 + diffuse granular 2 2 4° 1 1 1 2 3
a Marked epithelial proliferation.b Very large multinucleated cells in glomeruli.
One animal had mesangial deposits only. In all other specimens deposits were finely granular, predominantly on capillary walls.
?c.
a
A
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Fig. 6. Multinucleated giant cells which contain faintly periodic
acid Schifi (PAS)-posifive cytoplasmic material and occupy a
large portion of the glomerular capillary lumens of a renal biopsy
specimen taken from a nonproteinnric rabbit that had received
2250 mg of inulin B weekly for /4 weeks (PAS stain; ori?inal
magnification, x 230).
inulin-treated rabbits) or zymosan particles in various
stages of deterioration (in rabbits receiving zymosan).
These cells were clearly separated from the glomerular
basement membrane by endothelial cytoplasm, sug-
gesting that they may have originated as circulating
phagocytic cells (Fig. 7). Giant cell formation,
presumably originating in the reticuloendothelial
system or from trapped circulating phagocytic cells,
was also prominent in the lung, liver and spleen. When
present in large numbers, the giant cells disrupted the
normal tissue architecture.
In the nonproteinuric rabbits there was no obvious
endothelial or epithelial cell proliferation or consistent
increase in PMN's. In some rabbits the endothelial
cell cytoplasm appeared pale, with swollen nuclei.
Occasionally, rabbits given zymosan had localized
foci of PMN's in glomeruli, sometimes surrounding a
zymosan particle. Glomerular basement membranes
were of normal thickness and no vascular or inter-
stitial abnormalities were observed.
In addition to the previously decribed lesions, eight
of the 12 proteinuric rabbits had glomerular abnor-
malities characterized by a proliferation of endo-
capillary and mesangial cells with increased numbers
of PMN's in the glomerular tufts (Fig. 8). Serial tissue
specimens were available from some of these animals,
allowing us to follow the progression of the renal
damage. We found that later specimens showed a
number of hyalinized glomeruli and considerable renal
architectural destruction.
in kidneys of rabbits receiving inulin or zymosan
but not having proteinuria, TgG, C3 and C6 were
either not detectable by immunofluorescence or were
present focally in trace to 1 + granular deposits in 36
and 37 specimens, respectively (Table 4). Only one
rabbit (receiving zymosan) had C3 and C6 deposits in
the absence of definite IgG deposits.
Eight of the 12 proteinuric rabbits had 2 to 3+
IgG, C3 and C6 deposits. In seven rabbits these
deposits were finely granular, sometimes nearly
confluent and appeared almost linear, not unlike those
encountered in control rabbits with spontaneous
glomerulonephritis (Fig. 8). In one rabbit the deposits
were confined to the mesangium. No deposits were
found in two of the proteiuric rabbits, and the re-
maining two had trace to I + focal deposits similar to
those found in the nonproteinuric animals.
In almost all animals receiving zymosan, the acti-
vator particles could be detected in the glomeruli and
peritubular capillaries, and all such particles stained
brightly for C3 and C6. IgG was also found bound to
the particles in all animals that had antibodies to
zymosan.
Glornerular hypercellularity (largely endothelial and
mesangial), increased mesangial matrix, scattered
PMN's and thickening of the glomerular basement
membrane (GBM) accompanied by 1 to 3 + granular
immunofluorescent deposits of IgG and C3 were
found in three of the 25 control rabbits studied (Fig.
8). These three rabbits were proteinuric. On electron
microscopy irregularity of the subepithelial portion of
the GBM which suggested immune complex deposits
was apparent (Fig. 8). The electron density of these
irregularities was, however, not greatly different from
that of the basement membrane itself. The renal lesion
was indistinguishable from that of a spontaneous
glomerulonephritis found in about 5% of younger
rabbits (14 weeks of age) in our colony (Wilson, C. B.
and Ahinanti, F. R., unpublished observations). Nine
of the remaining 21 control rabbits had slight, focal
irregularity of the GBM by electron microscopy and
scant, variable immunofluorescent deposits of IgG
and C3, accompanied by only mild, minimal or no
histologic abnormality. These findings were similar to
those noted in the nonproteinuric experimental
rabbits (Table 4). The IgG and C3 deposits were
generally of equal intensity in the control glomeruli,
a
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Fig. 7. Electron microscopic appearance of a glomerular capillary from a rabbit that had received 2430 mg of Inulin C daily for 24 weeks.
Striated, crystalloid material (C) is seen occupying a large portion of an intraluminal cell (LC) which is surrounded by fenestrated
cytoplasm of an endothelial cell (EN). The glomerular basement membrane (GBM) is normal thickness. The epithelial cell (EP) foot
processes are generally well preserved; magnification x 14,000.
except in one rabbit in which C3 deposits predomina-
ted. The multinucleated giant cells so common in the
experimental rabbits were not observed in the control
rabbits.
Discussion
The aim of the present work was to study potentially
nephritogenic effects of acute or chronic daily activa-
tion of C via the alternate pathway using rabbits. We
found it possible to activate C repeatedly in vivo by
chronic administration of inulin or zymosan as
indicated by decreased serum concentrations of total
hemolytic C (CH5O), C3 and C6. Previous studies in
vivo and in vitro have shown that C activation by these
agents occurs via the alternate C pathway [8], although
when antizymosan antibodies are present, classical C
activation may occur as well. It seemed to us, then, that
such activation might produce deposition of C in
glomeruli and so lead to glomerular injury in two ways:
1) Upon systemic activation of C, components of C5
to C9 form a soluble complex with a sediment coeffi-
cient of 22.4 S [22], thus becoming by virtue of size,
potentially able to localize in glomerular capillaries
[23]; and/or 2) the agent activating C may become
trapped in the glomeruli and activate C3 to C9 in situ.
Either mode of deposition would result in release of
biologically active materials including substances
chemotactic for PMN's which could in turn induce
glomerular injury.
We found that C3 and C6, indeed, deposited in
glomeruli of rabbits given large, often lethal, doses of
inulin or zymosan acutely; however, considerable
fibrin deposits and, in some instances, traces of IgG
were also detected. Because large amounts of C
activator were given, it is probable that zymosan and,
possibly, inulin particles trapped in glomerular
capillaries induced activation of C3 to C9 with
subsequent activation of the coagulation system [24].
Indeed, in rabbits receiving zymosan, the particles
coated with C3 and C6 could be seen close to C3, C6
and larger fibrin deposits along capillary walls. It is
interesting to note that, although the glomeruli of some
of these animals showed many PMN's, proteinuria
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Fig. 8. Glomeruli from a proteinuric rabbit that had received 2430 mg of mu/in C daily for 20 weeks (A) and from a proteinuric
control rabbit (B). Endocapillary proliferation is prominent and increased numbers of polymorphonuclear leukocytes (—>) are
present within the glomerular capillary tufts. The glomerular basement membrane (GBM) is irregularly thickened. Intense,
nearly confluent, finely granular deposits of C6 (accompanied by Igo and C3) are present along the GBM of the immunofluores-
cently stained kidneys, suggesting immune complex deposition in both the experimental (C) and control rabbits (D). Striking
subepithelial irregularities (—>)of the GBM accompanied by fusion of the epithelial cell (EP) foot processes were found in both
experimental (E) and control rabbits (F). The electron density of the subepithelial deposits did not differ greatly from that
of the GBM itself. (A, B, PAS stain; x 160. C, D, indirect immunofluorescence using goat antirabbit C6 and fluorescein
isothiocyanate conjugated rabbit antigoat IgG as a second layer; x 250. E, F: x 17,500 and x 22,000, respectively.)
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was not detectable even when large amounts of
inulin were infused on several consecutive days. This
would suggest that, although the deposits had chemo-
tactic properties, they were not sufficiently close to, or
in prolonged enough contact with, the basement mem-
brane to induce functional damage.
In rabbits receiving a regimen of inulin or zymosan
for prolonged periods of time, our observations suggest
that repeated activation of the C system did not
produce glomerular deposition of C or glomerular
injury. Although giant cells were found within the
glomeruli, these were probably due to the particulate
form of the agent administered rather than to its
C-activating properties. This possibility is supported
by the electron microscopic demonstration of intra-
cellular inclusions of crystalloid material or zymosan
particles within these cells and the fact that the giant
cells occurred most frequently in animals given large
doses of inulin and zymosan. Interestingly, the often
severe structural glomerular alteration produced by
the accumulation of giant cells did not cause functional
defects.
Only 12 rabbits developed proteinuria (Table 2). In
eight of these, severe glomerular damage was indicated
by endothelial proliferation, increase in the number of
PMN's and, eventually, destruction of renal architec-
ture. C3 and C6 deposits were always associated with
granular IgG, suggesting immune and, probably,
classical C activation secondary to immune complex
deposition. In the four other proteinuric rabbits,
glomerular lesions were not so marked, and IgO, C3
and C6 deposits were either absent or present only
focally in trace to 1 + amounts. The antigen in these
presumed immune complexes was not likely to be
inulin, since antibodies to inulin could not be demon-
strated. Since antibodies capable of reacting with
intact zymosan particles were found, it is possible that
some of the proteins or polysaccharide present in
zymosan may have played a role in immune complex
formation. However, it is much more likely that the
lesions observed were secondary to a spontaneous
immune complex glomerulonephritis that occurs in
our colony. Several facts favor this possibility: the lack
of correlation of immunopathologic findings with the
amounts of inulin or zymosan injected, a similar low
incidence of glomerulonephritis in both the experi-
mental and control groups and the similar appearance
of histologic, immunofluorescent and electron micro-
scopic findings in the experimental and control
groups.
Several possibilities might explain our observation
that chronic C activation per se did not produce
glomerular damage. Perhaps systemic C activation was
not intense enough. Indeed, even after massive doses of
either activator, C consumption was never complete,
suggesting that the alternate C pathway was unable to
cause total C activation presumably due to a critical
limitation of one or more of its component proteins.
Additionally, part of the decrease in serum C concen-
trations may not have been due to C activation but to
depletion of some C component by adsorption onto the
zymosan or inulin particles. It should be stressed,
however, that activation of the coagulation system and
the appearance of PMN's after acute administration
suggest that the later C components were activated
with release of biologically active products. Alterna-
tively, it could be proposed that efficient C activation
did occur but that the large mol wt complexes thus
formed did not localize in glomerular capillaries. If
alternate pathway C activation does have a nephrito-
genic effect, it may be that in order for injury to occur
the activation must be localized in the glomeruli or
even in the glomerular capillary wall, neither of which
conditions was provided for in the present experi-
mental system.
Although it is not yet possible to exclude systemic
nonimmune C activation as an etiologic mechanism in
human glomerulonephritis, our findings suggest that
nonimmune C activation per se is insufficient to induce
glomerulonephritis in rabbits. In this context, it
should be noted that 70% of patients with CHGN
have IgG, Clq, C3 and C4 deposits in their glomeruli
at some time [5]; this observation may well imply that
if nonimmune C activation plays a role in the patho-
genesis of these lesions, it may do so only after injury
has been triggered by immune complexes and activa-
tion of the classical pathway. Our recent description of
two patterns of C component deposition in glomeruli
from patients with advancing glomerulonephritis
would also support this contention. In these patients
some glomeruli contain scant granular deposits of
immunoglobulin and initial C components (Clq, C4)
accompanied with much heavier granular deposits of
C3 and later-acting C components (CS, C6, CS) while
the majority of glomeruli contain only C3 and later
components. Since kidneys from patients with
advanced glomerulonephritis often contain only C3
and later C components, these observations would
suggest a transition from an immune-complex-
induced glomerulonephritis with perpetuation of
glomerular injury by an as yet unexplained activation
of the terminal and biologically active portion of the
C sequence.
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